Revolution Medicines (NASDAQ:RVMD – Get Free Report) and Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.
Valuation and Earnings
This table compares Revolution Medicines and Tonix Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Revolution Medicines | $11.58 million | 3,059.46 | -$1.13 billion | ($9.11) | -17.98 |
| Tonix Pharmaceuticals | $13.11 million | 4.39 | -$124.02 million | ($12.24) | -0.24 |
Tonix Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Revolution Medicines has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500.
Insider and Institutional Ownership
94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Revolution Medicines and Tonix Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Revolution Medicines | N/A | -84.51% | -51.97% |
| Tonix Pharmaceuticals | -420.45% | -80.97% | -70.18% |
Analyst Recommendations
This is a summary of recent recommendations for Revolution Medicines and Tonix Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Revolution Medicines | 1 | 1 | 21 | 1 | 2.92 |
| Tonix Pharmaceuticals | 1 | 0 | 1 | 2 | 3.00 |
Revolution Medicines currently has a consensus price target of $262.75, indicating a potential upside of 60.41%. Tonix Pharmaceuticals has a consensus price target of $22.33, indicating a potential upside of 654.50%. Given Tonix Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Revolution Medicines.
Summary
Tonix Pharmaceuticals beats Revolution Medicines on 8 of the 15 factors compared between the two stocks.
About Revolution Medicines
Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. is a U.S.-based biopharmaceutical company that develops and commercializes medicines for central nervous system disorders and pursues research programs in immunology, rare diseases and infectious diseases. Its product Tonmya (cyclobenzaprine hydrochloride sublingual tablets) received U.S. Food and Drug Administration approval in 2025 for the treatment of fibromyalgia in adults. The company also has a development pipeline that includes drug candidates and vaccine programs, including research targeting smallpox and mpox.
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
